Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 2/20 | 0.54 |
| ▸ | CDK1 | P06493 | 2/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.54 |
| ▸ | CDK2 | P24941 | 2/20 | 0.54 |
| ▸ | CDK7 | P50613 | 2/20 | 0.54 |
| ▸ | CDK9 | P50750 | 2/20 | 0.54 |
| ▸ | CCNH | P51946 | 2/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 9/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2540505 | 0.92 | BTK (0.49) | CCNT1CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL2546325 | 0.86 | CAMK2D (0.53) | CDK1CCNB1CDK2CDK7CCNH | |
| SCHEMBL2542180 | 0.85 | CCNT1 (0.58) | CCNT1CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL2547332 | 0.83 | JAK2 (0.53) | CCNT1CDK1CDK2CDK9KIT | |
| SCHEMBL2542192 | 0.82 | PLK1 (0.48) | CCNT1CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL2539863 | 0.82 | FLT3 (0.55) | CCNT1CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL2544054 | 0.81 | CCNT1 (0.54) | CCNT1CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL2543307 | 0.81 | CCNT1 (0.54) | CCNT1CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL2540539 | 0.80 | CCNT1 (0.55) | CCNT1CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL2542799 | 0.79 | FLT3 (0.55) | CDK1CCNB1CDK2CDK7CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303163-A1 | USE OF KINASE INHIBITORS IN PREVENTING AND TREATING INFLAMMATORY DISORDER | LUO YING (CN) | 2014-10-09 | — | — | US | claimed |
| US-8309550-B2 | Kinase inhibitors and their use as pharmaceutical agents | SHANGHAI GENOMICS, INC. (CN) | 2012-11-13 | — | — | US | claimed |
| US-20110263541-A1 | KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS | SHANGHAI GENOMICS, INC (CN) | 2011-10-27 | — | — | US | claimed |
| US-20140303163-A1 | USE OF KINASE INHIBITORS IN PREVENTING AND TREATING INFLAMMATORY DISORDER | LUO YING (CN) | 2014-10-09 | — | — | US | disclosed |
| US-8309550-B2 | Kinase inhibitors and their use as pharmaceutical agents | SHANGHAI GENOMICS, INC. (CN) | 2012-11-13 | — | — | US | disclosed |
| US-20110263541-A1 | KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS | SHANGHAI GENOMICS, INC (CN) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263541-A1 | KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS | MAP3K20, MAP3K1, MAP3K2 | CCNT1 1213/4885CDK1 129/4885CCNB1 1308/4885 |
| US-20140303163-A1 | USE OF KINASE INHIBITORS IN PREVENTING AND TREATING INFLAMMATORY DISORDER | NFKBIA, IRAK1, IRAK3 | CCNT1 3334/4885CDK1 465/4885CCNB1 2741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.